High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment
We investigated the serum concentration of endostatin in 84 patients with multiple myeloma (MM) and in 13 healthy controls. The level of measured anti-angiogenic agent was correlated with the phase and stage of the disease, and most importantly with clinical and laboratory parameters depicting the d...
Saved in:
Main Authors: | Halina Urbanska-Rys, Tadeusz Robak |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2003-01-01
|
Series: | Mediators of Inflammation |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09629350310001599675 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered
by: Pengfei Chen, et al.
Published: (2025-03-01) -
Illuminating the Shadows: Innovation in Advanced Imaging Techniques for Myeloma Precursor Conditions
by: Kara I. Cicero, et al.
Published: (2025-01-01) -
Chromothripsis in Treatment Resistance in Multiple Myeloma
by: Kyoung Joo Lee, et al.
Published: (2017-09-01) -
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01) -
Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study
by: Matthew A. Lee, et al.
Published: (2025-01-01)